SCHEMBL3544607

SCHEMBL3544607

NN=C1C(=O)Nc2ccccc21

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LRRK2 Q5S007 9/20 0.62
IDO1 P14902 3/20 0.62
CA1 P00915 3/20 0.58
CA2 P00918 3/20 0.58
ALDH1A1 P00352 2/20 0.58
MAPT P10636 2/20 0.58
CA12 O43570 1/20 0.58
CA9 Q16790 1/20 0.58
AGTR1 P30556 2/20 0.56
KMT2A Q03164 2/20 0.56
POLB P06746 1/20 0.56
TDO2 P48775 1/20 0.56
GALR3 O60755 1/20 0.56
MAOA P21397 1/20 0.55
MAOB P27338 1/20 0.55
PDGFRA P16234 1/20 0.55
FER P16591 1/20 0.55
LTK P29376 1/20 0.55
CDK8 P49336 1/20 0.55
ACVR1 Q04771 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5740660 1.00 LRRK2 (0.62) LRRK2IDO1CA1CA2ALDH1A1
SCHEMBL3613979 1.00 LRRK2 (0.62) LRRK2IDO1CA1CA2ALDH1A1
SCHEMBL12971379 0.83 LRRK2 (0.67) LRRK2IDO1ALDH1A1MAPTAGTR1
SCHEMBL12804786 0.83 LRRK2 (0.67) LRRK2IDO1ALDH1A1MAPTAGTR1
SCHEMBL12804785 0.83 LRRK2 (0.67) LRRK2IDO1ALDH1A1MAPTAGTR1
SCHEMBL13714143 0.83 MAOA (0.50) LRRK2IDO1CA1CA2ALDH1A1
SCHEMBL14468456 0.83 MAOA (0.50) LRRK2IDO1CA1CA2ALDH1A1
SCHEMBL1898719 0.80 LRRK2 (0.62) LRRK2IDO1ALDH1A1MAPTAGTR1
SCHEMBL16760895 0.80 LRRK2 (0.62) LRRK2IDO1ALDH1A1MAPTAGTR1
SCHEMBL7740292 0.80 LRRK2 (0.62) LRRK2IDO1ALDH1A1MAPTAGTR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210221794-A1 ISATIN DERIVATIVES KING SAUD UNIVERSITY (SA) 2021-07-22 US claimed
CN-102295647-B All-alkyl substituted triindenyl cyclopi trimeric-indole derivative and preparation method thereof UNIV EAST CHINA NORMAL 2013-07-17 CN claimed
CN-102295647-A All-alkyl substituted triindenyl cyclopi trimeric-indole derivative and preparation method thereof 2011-12-28 CN claimed
EP-0503349-B1 Hydrazone derivatives, their preparation and use NEUROSEARCH AS (DK) 1995-01-04 EP claimed
US-5164404-A HYDRAZONE DERIVATIVES AND THEIR USE NEUROSEARCH A/S (DK) 1992-11-17 US claimed
EP-0503349-A1 Hydrazone derivatives, their preparation and use NEUROSEARCH A/S (DK) 1992-09-16 EP claimed
US-12319674-B2 Isatin derivatives KING SAUD UNIVERSITY (SA) 2025-06-03 US disclosed
US-20240239773-A1 ISATIN DERIVATIVES KING SAUD UNIVERSITY (SA) 2024-07-18 US disclosed
CN-117945979-A Isatin derivative, preparation method thereof and application thereof in preparation of plant antibacterial drugs 陕西师范大学 2024-04-30 CN disclosed
US-11945809-B2 Isatin derivatives KING SAUD UNIVERSITY (SA) 2024-04-02 US disclosed
US-20230357213-A1 ISATIN DERIVATIVES KING SAUD UNIVERSITY (SA) 2023-11-09 US disclosed
US-20210221794-A1 ISATIN DERIVATIVES KING SAUD UNIVERSITY (SA) 2021-07-22 US disclosed
US-9828342-B2 Isatin derivatives, pharmaceutical compositions thereof, and methods of use thereof CITY OF HOPE (US) 2017-11-28 US disclosed
WO-2006101937-A1 ACYLHYDRAZONES AS KINASE MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2006-09-28 WO disclosed
US-6479528-B1 Methods for inhibiting or reversing tau filament formation polymerization NEURONAUTICS, INC. 2002-11-12 US disclosed
WO-2002060373-A2 INDOLE DERIVATIVES AND THEIR USES AS HEPARANASE INHIBITORS INSIGHT STRATEGY AND MARKETING LTD (IL) 2002-08-08 WO disclosed
EP-0503349-B1 Hydrazone derivatives, their preparation and use NEUROSEARCH AS (DK) 1995-01-04 EP disclosed
US-5164404-A HYDRAZONE DERIVATIVES AND THEIR USE NEUROSEARCH A/S (DK) 1992-11-17 US disclosed
US-5164404-A HYDRAZONE DERIVATIVES AND THEIR USE NEUROSEARCH A/S (DK) 1992-11-17 US disclosed
EP-0503349-A1 Hydrazone derivatives, their preparation and use NEUROSEARCH A/S (DK) 1992-09-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230357213-A1 ISATIN DERIVATIVES HASPIN, BRCA1, VHL LRRK2 4414/4885IDO1 280/4885CA1 4228/4885
US-12319674-B2 Isatin derivatives HASPIN, BRCA1, VHL LRRK2 4414/4885IDO1 280/4885CA1 4228/4885
US-20240239773-A1 ISATIN DERIVATIVES HASPIN, BRCA1, VHL LRRK2 4414/4885IDO1 280/4885CA1 4228/4885
US-20210221794-A1 ISATIN DERIVATIVES HASPIN, MCL1, BRCA1 LRRK2 622/4885IDO1 826/4885CA1 248/4885
US-11945809-B2 Isatin derivatives HASPIN, BRCA1, VHL LRRK2 4414/4885IDO1 280/4885CA1 4228/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.